Market Overview

Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

Share:
Related GALT
Mid-Day Market Update: Thursday's Movers, China, Tesla And More
Morning Market Gainers

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse the primary kidney disease associated with diabetes, called diabetic nephropathy, the leading cause of kidney failure, dialysis and kidney transplant. GR-MD-02 is the Company's lead galectin inhibitor in development for the treatment of liver fibrosis, including non-alcoholic steatohepatitis (NASH) liver disease.

Posted-In: News

 

Related Articles (GALT)

Get Benzinga's Newsletters